本文選題：藥價(jià)談判　切入點(diǎn)：專利藥　出處：《上海醫(yī)藥工業(yè)研究院》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：多年以來(lái),我國(guó)藥品價(jià)格虛高現(xiàn)象屢見不鮮,尤其是進(jìn)口的專利藥品由于臨床療效突出,加之缺乏市場(chǎng)競(jìng)爭(zhēng),在我國(guó)長(zhǎng)期處于壟斷地位,藥品價(jià)格普遍居高不下。專利藥品由于具有一定的市場(chǎng)保護(hù)期限,無(wú)法與普通藥品一樣,以市場(chǎng)競(jìng)爭(zhēng)形成藥品價(jià)格,因此,需要采取統(tǒng)一談判的方式,將專利藥品價(jià)格控制在合理的區(qū)間范圍內(nèi),談判模式形成專利藥價(jià)格也是國(guó)際通行的方式。目前我國(guó)的藥品價(jià)格談判工作尚處于初探階段,沒(méi)有形成成熟系統(tǒng)的藥品價(jià)格談判模式。為了給國(guó)家談判工作中品種的選擇提供一定參考,最終完善我國(guó)藥價(jià)談判的制度體系,本文立足于國(guó)家藥品價(jià)格談判的品種,從專利藥品種角度出發(fā),深入分析專利藥產(chǎn)品的特征和使用現(xiàn)狀,首先對(duì)專利藥產(chǎn)品提出遴選原則和篩選辦法,其次對(duì)專利藥品相關(guān)影響因素進(jìn)行具體分析,篩選出重要的評(píng)價(jià)指標(biāo),賦予相對(duì)合理的權(quán)重,并通過(guò)首批談判品種對(duì)結(jié)果進(jìn)行驗(yàn)證,最終形成專利藥價(jià)格談判品種的評(píng)價(jià)體系。本文的研究方法有六種,分別是專家咨詢、文獻(xiàn)調(diào)研、調(diào)查問(wèn)卷、實(shí)證驗(yàn)證、定性分析和定量統(tǒng)計(jì)分析法。通過(guò)對(duì)專利藥利益相關(guān)方的分析,確定了專利藥談判品種的五大遴選原則;并從疾病、品種和企業(yè)三個(gè)角度闡述了專利藥談判品種遴選的具體方法;最后從不同角度分析專利藥談判品種相關(guān)指標(biāo),形成了5個(gè)維度的初級(jí)指標(biāo),14個(gè)定性指標(biāo)以及眾多觀測(cè)指標(biāo)。通過(guò)問(wèn)卷調(diào)查和專家咨詢的方式對(duì)二級(jí)指標(biāo)賦予一定權(quán)重,其次對(duì)指標(biāo)體系進(jìn)行實(shí)證研究,根據(jù)觀測(cè)指標(biāo)對(duì)專利藥產(chǎn)品進(jìn)行具體的衡量和評(píng)價(jià),形成專利藥產(chǎn)品評(píng)價(jià)的最終結(jié)果。通過(guò)首批談判的三個(gè)品種,對(duì)評(píng)價(jià)體系進(jìn)行進(jìn)一步的驗(yàn)證,三個(gè)品種評(píng)價(jià)的結(jié)果均為有談判價(jià)值,表明指標(biāo)體系較為合理。本文的創(chuàng)新點(diǎn)主要在于選題新穎,研究?jī)?nèi)容具有實(shí)際意義,研究成果具有前瞻性。國(guó)家藥品價(jià)格談判正處于首批試點(diǎn)階段,是當(dāng)前國(guó)家的熱點(diǎn)話題,本文通過(guò)定性結(jié)合定量的方法,理論結(jié)合實(shí)證的方法,以及專家咨詢的方法,針對(duì)談判品種進(jìn)行深入研究。
[Abstract]:For many years, the phenomenon of false high drug prices has been common in our country, especially because of the outstanding clinical efficacy of imported patented drugs and the lack of market competition, they have been in a monopoly position for a long time in our country. Drug prices are generally high. Because patent drugs have a certain period of market protection, they are unable to form drug prices in the same way as ordinary medicines by market competition. Therefore, it is necessary to adopt a unified negotiation method. To control the price of patent drugs within a reasonable range, the negotiation mode is also a common mode in the world. At present, the negotiation of drug prices in our country is still in the preliminary stage. In order to provide a certain reference for the selection of varieties in the national negotiations and finally perfect the institutional system of drug price negotiations in China, this paper is based on the varieties of the national drug price negotiations. From the point of view of the variety of patent drugs, the characteristics and current situation of patent drug products are analyzed in depth. Firstly, the selection principles and screening methods of patent drug products are put forward. Secondly, the related factors of patent drugs are analyzed concretely. The important evaluation index is screened out, the relative reasonable weight is given, and the result is verified by the first batch of negotiated varieties. Finally, the evaluation system of the patented drug price negotiation variety is formed. There are six kinds of research methods in this paper, which are expert consultation, respectively. Literature investigation, questionnaire, empirical verification, qualitative analysis and quantitative statistical analysis. Through the analysis of the stakeholders of patent drugs, the paper determines the five principles of selection of patent drugs negotiated varieties; and from the disease, This paper expounds the specific methods of variety selection in patent drug negotiation from three angles: variety and enterprise. Finally, it analyzes the related indexes of patent drug negotiation from different angles. It forms five dimensions of primary indicators, 14 qualitative indicators and many observation indicators. Through questionnaires and expert consultation, the secondary indicators are given a certain weight, and then the index system is empirically studied. According to the measurement and evaluation of the patent drug products, the final results of the patent drug product evaluation are formed. The evaluation system is further verified through the first three negotiated varieties. The results of the evaluation of the three varieties are of negotiation value, indicating that the index system is reasonable. The innovation of this paper is mainly due to the novelty of the selected topics and the practical significance of the research contents. The research results are forward-looking. The national drug price negotiations are in the first pilot stage, which is a hot topic in our country. This paper combines qualitative and quantitative methods, theoretical and empirical methods, as well as expert consultation methods. Carry on the thorough research to the negotiation variety.
【學(xué)位授予單位】：上海醫(yī)藥工業(yè)研究院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R95

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李國(guó)鋒;鄭文華;本刊編輯部;張思樂(lè);;天價(jià)專利藥,不道德?[J];家庭藥師;2011年07期

2 葉露;武瑞雪;;專利藥的定價(jià)與補(bǔ)償國(guó)際比較[J];中國(guó)醫(yī)療保險(xiǎn);2009年04期

3 張方;朱越;;加拿大專利藥品政府管制定價(jià)政策介紹[J];中國(guó)藥物經(jīng)濟(jì)學(xué);2012年01期

4 沈路;“仿”好到期專利藥[J];醫(yī)藥世界;2004年12期

5 沈晗;徐懷伏;;發(fā)展中國(guó)家專利藥品高價(jià)問(wèn)題及對(duì)策研究[J];上海醫(yī)藥;2008年09期

6 姜成菊;;我國(guó)過(guò)期專利藥與仿制藥價(jià)格及使用現(xiàn)狀分析[J];首都醫(yī)藥;2013年22期

7 孫文;;制藥業(yè):環(huán)境變了,商業(yè)模式一定要變[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2006年03期

8 林坤;;新政時(shí)期:藥業(yè)上演仿制暗戰(zhàn)[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2007年06期

9 ;加拿大 專利藥品生產(chǎn)和價(jià)格控制制度[J];醫(yī)藥世界;2007年05期

10 江一帆;藥品創(chuàng)新與仿制的對(duì)弈[J];首都醫(yī)藥;2002年07期

相關(guān)重要報(bào)紙文章 前10條

1 中國(guó)藥科大學(xué)國(guó)際醫(yī)藥商學(xué)院 沈晗　徐懷伏;專利藥品高價(jià)的因果及對(duì)策[N];中國(guó)醫(yī)藥報(bào);2009年

2 沈陽(yáng)藥科大學(xué)工商管理學(xué)院副教授 張方;對(duì)專利藥價(jià)專立監(jiān)管[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

3 易瑤;政府統(tǒng)一制定專利藥價(jià)格[N];健康報(bào);2008年

4 賈戈;在國(guó)際比較中調(diào)控藥價(jià)[N];中國(guó)經(jīng)濟(jì)導(dǎo)報(bào);2008年

5 新訊;美國(guó)——專利藥失去保護(hù)堪喜[N];醫(yī)藥經(jīng)濟(jì)報(bào);2000年

6 顧潤(rùn)豐　孫長(zhǎng)龍;企業(yè)應(yīng)如何延長(zhǎng)專利藥品保護(hù)期？[N];中國(guó)知識(shí)產(chǎn)權(quán)報(bào);2012年

7 沈陽(yáng)藥科大學(xué)副教授 張方;管控韁繩牽住高價(jià)專利藥[N];醫(yī)藥經(jīng)濟(jì)報(bào);2012年

8 本報(bào)記者 段玉清;專利藥大量到期 四川藥企等來(lái)機(jī)遇[N];四川日?qǐng)?bào);2013年

9 本報(bào)記者 張旭;專利藥品利潤(rùn)率與可及性[N];中國(guó)醫(yī)藥報(bào);2014年

10 駐京記者 金豐杰;禮來(lái)與諾華的“中國(guó)信心”[N];醫(yī)藥經(jīng)濟(jì)報(bào);2003年

相關(guān)博士學(xué)位論文 前1條

1 劉嬋;制藥企業(yè)的知識(shí)產(chǎn)權(quán)運(yùn)用行為與政府政策分析[D];東北財(cái)經(jīng)大學(xué);2014年

相關(guān)碩士學(xué)位論文 前2條

1 榮雪菁;中國(guó)專利藥品價(jià)格比較及藥品談判采購(gòu)研究[D];山東大學(xué);2017年

2 陳姣姣;論我國(guó)專利藥與仿制藥規(guī)制體系完善[D];華東政法大學(xué);2014年

，

本文編號(hào)：1587900